May 06, 2026 | Bayer Acquires Perfuse for $2.45B in Ophthalmology; Novo Wegovy Pill Posts $355M Q1

Bayer bets up to $2.45B on glaucoma drug maker PerfuseTherapeutics — its biggest pharma deal in years. Novo's oral Wegovy hits $355M in Q1, the strongest GLP-1 launch by volume in the US. Plus UCB's $2.2B Candid deal, GSK's $1B SiranBio siRNA licensing, Lilly's $4.5B manufacturing pledge, and Sanofi walks away from the FDA's CNPV program.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Bayer, PerfuseTherapeutics, PER-001, glaucoma, diabetic retinopathy, ophthalmology, NovoNordisk, Wegovy, oral semaglutide, obesity, GLP-1, UCB, Candid Therapeutics,bispecific antibodies, autoimmune, GSK, SiranBio, siRNA, ALK7, cardiometabolic,Eli Lilly, manufacturing, Sanofi, Tzield, teplizumab, CNPV, VYVGART, Argenx,myasthenia gravis, Viridian, thyroid eye disease, Celcuity, ASCO, IRA, drugpricing, MFN, Avalo Therapeutics, CellCentric, Latus Bio, Cytokinetics,Madrigal, MASH, BioNTech, Novartis, Lilly, AbbVie, Amgen